

**NEUROKININ A INCREASES SHORT-CIRCUIT CURRENT ACROSS
RAT COLONIC MUCOSA: A ROLE FOR VASOACTIVE
INTESTINAL POLYPEPTIDE**

BY XIAO-YING TIEN*, LANE J. WALLACE, JAMES F. KACHUR,
SUZANNE WON-KIM AND TIMOTHY S. GAGINELLA†

*From the Division of Pharmacology, College of Pharmacy, The Ohio State University,
Columbus, OH 43210 and Searle Research and Development, Skokie, IL 60077, USA*

(Received 4 October 1990)

SUMMARY

1. Neurokinin A (NKA) is a mammalian tachykinin distributed principally in the nervous system, including the myenteric innervation of the gut.

2. NKA may be involved in neurogenic inflammation and as a modulatory factor in the diarrhoea associated with mucosal inflammation of inflammatory bowel disease (ulcerative colitis).

3. We evaluated the effect of NKA on the short-circuit current I_{sc} , assumed to reflect electrogenic chloride secretion, across muscle-stripped rat colonic mucosa mounted in Ussing chambers.

4. Serosal addition of NKA produced a concentration-dependent (0.1–100 nM) increase in I_{sc} with an EC_{50} (half-maximal effective concentration) value of 7.5 nM. The maximum (mean \pm s.e.m.) increase in I_{sc} ($\mu A/cm^2$) for NKA was 111 ± 10 .

5. Tetrodotoxin (0.5 μM) and bumetanide (10 μM), but not atropine (1.0 μM), hexamethonium (100 μM) or pyrilamine (10 μM), significantly inhibited NKA-induced increases in I_{sc} .

6. The response to NKA was attenuated by 45 min pre-treatment with antisera raised against vasoactive intestinal polypeptide (VIP). Moreover, prior desensitization to VIP attenuated the effect of NKA.

7. These studies suggest that NKA increases I_{sc} in rat colon, in part, through a non-cholinergic neural mechanism involving VIP.

INTRODUCTION

Neurokinin A (NKA, substance k, neuromedin L) is a mammalian tachykinin (Kangawa, Minamino, Fukuda & Matsuo, 1983; Kimura, Okada, Sugita, Kanagawa & Manekata, 1983), derived from β -preprotachykinin A and γ -preprotachykinin A (Maggio, 1988). It shares a common C-terminus and co-exists with other tachykinins

* Present address: Department of Physiology/Biophysiology, College of Medicine, Case Western Reserve University, 2119 Abington Road, Cleveland, OH 44106, USA.

† To whom reprint requests should be sent at the Department of Gastrointestinal Disease Research, Searle Research and Development, 4901 Searle Parkway, Skokie, IL 60077, USA.

in the same subpopulation of neurons, and therefore may also act as a neurotransmitter (Minamino, Kangawa, Fukuda & Matsuo, 1984; Dalsgaard, Haegerstrand, Theodorsson-Norheim, Brodin & Hokfelt, 1985; Dockray, 1987).

Neurogenic inflammation, characterized by vasodilatation, plasma extravasation and smooth muscle contraction initiated by release of proinflammatory mediators from sensory unmyelinated afferent nerve endings, may be a contributing factor in the pathophysiology of inflammatory bowel disease (Mayer, Raybould & Koelbel, 1988). Neurokinin A is a candidate mediator in neurogenic inflammation. It is localized in sensory neurons (Hua, Theodorsson-Norheim, Brodin, Lundberg & Hokfelt, 1985), increases vascular permeability and is a vasodilator (Foreman, 1987). Receptor binding sites for neurokinin A are expressed by cells mediating inflammatory and immune responses (Mantyh, Mantyh, Gates, Virna & Maggio, 1988). Tachykinins may affect inflammation by increasing mast cell secretion, promoting monocyte chemotaxis and stimulating phagocytosis and lysosomal enzyme release by neutrophils (Shanahan & Anton, 1988).

Recently, NKA was shown under short-circuit conditions to cause net electrolyte secretion in the canine tracheal epithelium (Rangachari, McWade & Donoff, 1987; Tamaoki, Ueki, Widdicombe & Nadel, 1988) and the guinea-pig jejunum (Mathison & Davidson, 1989). Since the colonic mucosal secretory response to NKA has not been reported, and secretory diarrhoea is associated with ulcerative colitis, we investigated the effects and mechanism of action of NKA on rat colonic mucosa *in vitro*.

Part of this work has been presented in abstract form (Tien, Wallace & Gaginella, 1988).

METHODS

Tissue preparation

Male Sprague-Dawley rats (250–400 g) were killed by cervical dislocation, and the distal colon was excised. The colon was opened and rinsed with ice-cold saline solution (0.9% w/v NaCl). The circular and longitudinal muscle layers were stripped off with a pair of fine forceps. Pieces of muscle-stripped mucosa were mounted as flat sheets in Ussing chambers (0.64 cm²) and bathed with buffered physiological saline solution composed of (mM): NaCl, 120.2; KCl, 5.9; CaCl₂, 2.5; MgCl₂, 1.2; NaH₂PO₄, 1.2; NaHCO₃, 25; glucose, 11.1 (pH 7.4, 37 °C), gassed with 95% O₂ and 5% CO₂.

Electrical measurements

Electrical potential difference (PD) was monitored at the beginning of each experiment with a pair of saturated KCl-agar (3%) bridges placed on each side of the tissue. The circuit was completed with calomel half-cell electrodes connected to a DVC 1000 voltage clamp (WPI Instruments, New Haven, CT, USA). Short-circuit current (I_{sc}) was applied through silver-silver chloride electrodes to the tissue to clamp open-circuit PD (potential difference) at zero, and compensation was made for fluid resistance. Initial tissue conductance (G_t) was calculated from the values of I_{sc} and PD according to Ohm's law. The reciprocal of G_t (mS/cm²) times 1000 equals the tissue resistance (R , Ω cm²).

Concentration-response curves

After mounting, the tissues were allowed to equilibrate for at least 30–60 min; effects on presumed electrogenic chloride secretion were monitored as changes in I_{sc} . The concentration required to increase I_{sc} by 50% (EC₅₀) was calculated from the curves by non-linear least-squares regression.

Effects of antagonists

Antagonists were added to the serosal side of the tissue for various times (see individual drugs below) prior to agonist addition. If blockade was observed, bethanechol (0.4 mM) or aminophylline (20 mM) was added after the agonist response to ensure that antagonism, rather than poor tissue viability, was responsible for the lack of response. Antagonist controls were conducted on a separate tissue from the same animals.




Fig. 1. Representative effect of NKA (μM) on I_{sc} after a single concentration (A) and following cumulative addition (B).

VIP antisera studies

VIP antisera was used to assess a role for VIP in the response to NKA. The VIP antiserum was used at a final dilution of 1:200. Each tissue preparation treated with VIP antiserum was compared with a control tissue from the same animal. Basal I_{sc} values and conductance were comparable in VIP-antisera treated and control tissues.

Materials

NKA, VIP, TTX, hexamethonium and pyrilamine were obtained from Sigma (St Louis, MO, USA), and bumetanide was obtained from Hoffmann-La Roche Inc., Nutley, NJ, USA. Agents not soluble in distilled water or saline were dissolved in dimethyl sulphoxide (DMSO). Equivalent amounts of DMSO (without drug) added to the serosal side did not affect I_{sc} . VIP antisera (Ras 71651-N, rabbit) was purchased from Peninsula Laboratories, San Carlos, CA, USA.

Statistical analysis

All values are expressed as the means \pm s.e.m. The Student's paired or unpaired *t* test was used for testing statistical significance.

RESULTS

Effect of NKA on I_{sc}

NKA evoked a rapid but transient increase in I_{sc} upon serosal addition (Fig. 1). The responses were concentration dependent over a range of 0.5–100 nM (Fig. 2); the EC_{50} value was determined to be 7.5 nM. The maximum response to NKA was $111 \pm 10 \mu\text{A}/\text{cm}^2$ ($n = 26$ tissues from thirteen animals).




Fig. 2. Concentration-response curve (serosal addition) for NKA-induced increases I_{sc} across rat colonic mucosa. Results are expressed as the change in I_{sc} ($\mu A/cm^2$) above baseline *vs.* log concentration of NKA. Symbols and bars represent the means \pm s.e.m. of determinations for at least twelve animals. The maximal increase in I_{sc} was achieved at 10^{-7} – 10^{-6} M.




Fig. 3. Effects of tetrodotoxin (TTX), atropine and hexamethonium against NKA (50 nM). Inhibitors were added 10 min before NKA. Results are expressed as means \pm s.e.m. of three to eight animals. * $P < 0.05$.

Effects of inhibitors

To substantiate that the NKA-evoked increase in I_{sc} was due to active chloride ion secretion, tissues were incubated with bumetanide (10 μM , 30 min) before adding NKA to the tissue bath. Responses to a maximally effective concentration (50 nM)

of NKA were significantly ($P < 0.001$) reduced by serosal addition of bumetanide to $14 \pm 4\%$ of control. Unidirectional flux measurements with $^{36}\text{Cl}^-$ could not be conducted due to the transient nature of the response.

TTX ($0.5 \mu\text{M}$) inhibited by 93% the I_{sc} response to 50 nM-NKA (Fig. 3). Atropine ($1 \mu\text{M}$, 10 min), which completely inhibited the response to 0.4 mM-bethanechol, had




Fig. 4. Effects of the H_1 receptor antagonist pyrilamine ($10 \mu\text{M}$) against 1 mM-histamine and NKA (50 nM). The antagonist was added 10 min prior to agonists. All drugs were added to the serosal side. Data are expressed as means \pm S.E.M. for determinations from at least six animals. * $P < 0.001$.

no significant effect on responses elicited by NKA; the ganglionic blocker, hexamethonium, also failed to inhibit the response to NKA (Fig. 1).

Because other neurokinins are reported to release histamine from mast cells (Erjavec, Lembeck, Florjanc-Irman, Skofitsch, Donnerer, Saria & Holzer, 1981; Foreman, 1987), the histamine receptor H_1 antagonist, pyrilamine, was used to determine if it would block the NKA-induced response. Pylamine ($10 \mu\text{M}$, 15 min) significantly blocked the histamine (1 mM) but not the NKA (50 nM) response (Fig. 4).

The effect of VIP antisera on the I_{sc} response to NKA was examined. A dilution of 1:200 attenuated both the NKA response (Fig. 5A) and the response to VIP (Fig. 5B). However, pre-treatment with non-specific rabbit serum (1:200) or pre-neutralized VIP antiserum did not affect the response to NKA.

Desensitization studies

After stimulation of the tissues with NKA, subsequent additions of the same concentration of the peptide failed to produce a response, indicating homologous

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.